266 related articles for article (PubMed ID: 21382717)
21. QSAR Modeling, Molecular Docking and Molecular Dynamics Simulations Studies of Lysine-Specific Demethylase 1 (LSD1) Inhibitors as Anticancer Agents.
Abdizadeh R; Heidarian E; Hadizadeh F; Abdizadeh T
Anticancer Agents Med Chem; 2021; 21(8):987-1018. PubMed ID: 32698753
[TBL] [Abstract][Full Text] [Related]
22. Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence.
Hanessian S; Auzzas L; Giannini G; Marzi M; Cabri W; Barbarino M; Vesci L; Pisano C
Bioorg Med Chem Lett; 2007 Nov; 17(22):6261-5. PubMed ID: 17892933
[TBL] [Abstract][Full Text] [Related]
23. Development and Structural Evaluation of N-Alkylated trans-2-Phenylcyclopropylamine-Based LSD1 Inhibitors.
Niwa H; Sato S; Handa N; Sengoku T; Umehara T; Yokoyama S
ChemMedChem; 2020 May; 15(9):787-793. PubMed ID: 32166890
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and evaluation of 3-amino/guanidine substituted phenyl oxazoles as a novel class of LSD1 inhibitors with anti-proliferative properties.
Dulla B; Kirla KT; Rathore V; Deora GS; Kavela S; Maddika S; Chatti K; Reiser O; Iqbal J; Pal M
Org Biomol Chem; 2013 May; 11(19):3103-7. PubMed ID: 23575971
[TBL] [Abstract][Full Text] [Related]
25. Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation.
Schulz-Fincke J; Hau M; Barth J; Robaa D; Willmann D; Kürner A; Haas J; Greve G; Haydn T; Fulda S; Lübbert M; Lüdeke S; Berg T; Sippl W; Schüle R; Jung M
Eur J Med Chem; 2018 Jan; 144():52-67. PubMed ID: 29247860
[TBL] [Abstract][Full Text] [Related]
26. Tranylcypromine and 6-trifluoroethyl thienopyrimidine hybrid as LSD1 inhibitor.
Wang X; Su M; Li Y; Liu T; Wang Y; Chen Y; Tang L; He YP; Ding X; Yu F; Shen J; Li J; Zhou Y; Chen YL; Xiong B
Bioorg Med Chem Lett; 2019 Mar; 29(6):844-847. PubMed ID: 30713023
[TBL] [Abstract][Full Text] [Related]
27. Identification of cell-active lysine specific demethylase 1-selective inhibitors.
Ueda R; Suzuki T; Mino K; Tsumoto H; Nakagawa H; Hasegawa M; Sasaki R; Mizukami T; Miyata N
J Am Chem Soc; 2009 Dec; 131(48):17536-7. PubMed ID: 19950987
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and biological activity of optically active NCL-1, a lysine-specific demethylase 1 selective inhibitor.
Ogasawara D; Suzuki T; Mino K; Ueda R; Khan MN; Matsubara T; Koseki K; Hasegawa M; Sasaki R; Nakagawa H; Mizukami T; Miyata N
Bioorg Med Chem; 2011 Jun; 19(12):3702-8. PubMed ID: 21227703
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and evaluation of curcumin analogues as potential thioredoxin reductase inhibitors.
Qiu X; Liu Z; Shao WY; Liu X; Jing DP; Yu YJ; An LK; Huang SL; Bu XZ; Huang ZS; Gu LQ
Bioorg Med Chem; 2008 Sep; 16(17):8035-41. PubMed ID: 18678491
[TBL] [Abstract][Full Text] [Related]
30. Crystal structure of histone demethylase LSD1 and tranylcypromine at 2.25 A.
Mimasu S; Sengoku T; Fukuzawa S; Umehara T; Yokoyama S
Biochem Biophys Res Commun; 2008 Feb; 366(1):15-22. PubMed ID: 18039463
[TBL] [Abstract][Full Text] [Related]
31. Novel potent inhibitors of the histone demethylase KDM1A (LSD1), orally active in a murine promyelocitic leukemia model.
Trifirò P; Cappa A; Brambillasca S; Botrugno OA; Cera MR; Zuffo RD; Dessanti P; Meroni G; Thaler F; Villa M; Minucci S; Mercurio C; Varasi M; Vianello P
Future Med Chem; 2017 Jul; 9(11):1161-1174. PubMed ID: 28722470
[TBL] [Abstract][Full Text] [Related]
32. Facile synthesis of substituted trans-2-arylcyclopropylamine inhibitors of the human histone demethylase LSD1 and monoamine oxidases A and B.
Gooden DM; Schmidt DM; Pollock JA; Kabadi AM; McCafferty DG
Bioorg Med Chem Lett; 2008 May; 18(10):3047-51. PubMed ID: 18242989
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis and evaluation of γ-turn mimetics as LSD1-selective inhibitors.
Ota Y; Miyamura S; Araki M; Itoh Y; Yasuda S; Masuda M; Taniguchi T; Sowa Y; Sakai T; Itami K; Yamaguchi J; Suzuki T
Bioorg Med Chem; 2018 Feb; 26(3):775-785. PubMed ID: 29331452
[TBL] [Abstract][Full Text] [Related]
34. Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans-2-phenylcyclopropylamine.
Yang M; Culhane JC; Szewczuk LM; Jalili P; Ball HL; Machius M; Cole PA; Yu H
Biochemistry; 2007 Jul; 46(27):8058-65. PubMed ID: 17569509
[TBL] [Abstract][Full Text] [Related]
35. [1,2,3]Triazolo[4,5-d]pyrimidine derivatives incorporating (thio)urea moiety as a novel scaffold for LSD1 inhibitors.
Li ZH; Ma JL; Liu GZ; Zhang XH; Qin TT; Ren WH; Zhao TQ; Chen XH; Zhang ZQ
Eur J Med Chem; 2020 Feb; 187():111989. PubMed ID: 31881456
[TBL] [Abstract][Full Text] [Related]
36. Development of (4-Cyanophenyl)glycine Derivatives as Reversible Inhibitors of Lysine Specific Demethylase 1.
Mould DP; Alli C; Bremberg U; Cartic S; Jordan AM; Geitmann M; Maiques-Diaz A; McGonagle AE; Somervaille TCP; Spencer GJ; Turlais F; Ogilvie D
J Med Chem; 2017 Oct; 60(19):7984-7999. PubMed ID: 28892629
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis, and structure-activity relationship of novel LSD1 inhibitors based on pyrimidine-thiourea hybrids as potent, orally active antitumor agents.
Ma LY; Zheng YC; Wang SQ; Wang B; Wang ZR; Pang LP; Zhang M; Wang JW; Ding L; Li J; Wang C; Hu B; Liu Y; Zhang XD; Wang JJ; Wang ZJ; Zhao W; Liu HM
J Med Chem; 2015 Feb; 58(4):1705-16. PubMed ID: 25610955
[TBL] [Abstract][Full Text] [Related]
38. Targeting Cancer with PCPA-Drug Conjugates: LSD1 Inhibition-Triggered Release of 4-Hydroxytamoxifen.
Ota Y; Itoh Y; Kaise A; Ohta K; Endo Y; Masuda M; Sowa Y; Sakai T; Suzuki T
Angew Chem Int Ed Engl; 2016 Dec; 55(52):16115-16118. PubMed ID: 27882656
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis, and biological evaluation of 5-aminotetrahydroquinoline-based LSD1 inhibitors acting on Asp375.
Yan J; Gu Y; Sun Y; Zhang Z; Zhang X; Wang X; Wu T; Zhao D; Cheng M
Arch Pharm (Weinheim); 2021 Aug; 354(8):e2100102. PubMed ID: 33987875
[TBL] [Abstract][Full Text] [Related]
40. Discovery of novel tranylcypromine-based derivatives as LSD1 inhibitors for gastric cancer treatment.
Ma QS; Zhang YF; Li CY; Zhang WX; Yuan L; Niu JB; Song J; Zhang SY; Liu HM
Eur J Med Chem; 2023 May; 251():115228. PubMed ID: 36881982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
